Physician profile
Chad B Speth
NPI 1851301246
$897.55
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $531 · 2023: $199 · 2024: $49.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233.75 | 2021-2024 | |
| Alkermes, INC. | $141.80 | 2022-2024 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $95.70 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $83.71 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $71.94 | 2022 | |
| Lundbeck LLC | $56.55 | 2021-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $46.28 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $46.10 | 2022-2023 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.30 | 2022 | |
| Ironshore Pharmaceuticals INC. | $28.53 | 2022 | |
| Axsome Therapeutics, INC. | $15.70 | 2023 | Auvelity |
| Tris Pharma INC | $14.27 | 2023 | Dyanavel Xr |
| Lucid Diagnostics INC. | $13.49 | 2023 | |
| Alfasigma USA, INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Speth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.